Sangamo Therapeutics, Inc. – LSE:0R1D.L
Sangamo Therapeutics stock price today
Sangamo Therapeutics stock price monthly change
Sangamo Therapeutics stock price quarterly change
Sangamo Therapeutics stock price yearly change
Sangamo Therapeutics key metrics
Market Cap | 522.66M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.86 |
Revenue | 18.75M |
EBITDA | -133.73M |
Income | -328.05M |
Revenue Q/Q | -99.69% |
Revenue Y/Y | -92.21% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -713.04% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSangamo Therapeutics stock price history
Sangamo Therapeutics stock forecast
Sangamo Therapeutics financial statements
| Jun 2023 | 6.83M | -114.50M | -1675.29% |
|---|---|---|---|
| Sep 2023 | 9.39M | -104.16M | -1108.35% |
| Dec 2023 | 2.04M | -60.29M | -2952.79% |
| Mar 2024 | 481K | -49.08M | -10205.61% |
| Sep 2025 | 7.75M | -15.39M | -198.63% |
|---|---|---|---|
| Oct 2025 | 7.75M | -13.82M | -178.4% |
| Dec 2025 | 34.2M | -5.41M | -15.82% |
| Mar 2026 | 658.25K | -23.39M | -3553.4% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 325074000 | 91.43M | 28.13% |
|---|---|---|---|
| Sep 2023 | 219697000 | 84.77M | 38.59% |
| Dec 2023 | 165320000 | 82.43M | 49.86% |
| Mar 2024 | 128961000 | 72.26M | 56.04% |
| Jun 2023 | -60.71M | 42.46M | 6.51M |
|---|---|---|---|
| Sep 2023 | -47.29M | 37.62M | -100K |
| Dec 2023 | -50.53M | 37.70M | 167K |
| Mar 2024 | -48.66M | 35.84M | 22.12M |
Sangamo Therapeutics alternative data
| Aug 2023 | 478 |
|---|---|
| Sep 2023 | 478 |
| Oct 2023 | 478 |
| Nov 2023 | 478 |
| Dec 2023 | 478 |
| Jan 2024 | 478 |
| Feb 2024 | 478 |
| Mar 2024 | 405 |
| Apr 2024 | 405 |
| May 2024 | 405 |
| Jun 2024 | 405 |
| Jul 2024 | 405 |
Sangamo Therapeutics other data
| Insider | Compensation |
|---|---|
Dr. Alexander D. Macrae (1963) Chief Executive Officer, Pres & Director | $1,140,000 |
Dr. R. Andrew Ramelmeier Ph.D. (1962) Executive Vice President of Technical Operations | $542,210 |
Mr. Gary H. Loeb (1970) Executive Vice President, Gen. Counsel, Chief Compliance Office & Sec. | $487,880 |
Mr. Sung H. Lee (1971) Executive Vice President & Chief Financial Officer | $320,190 |
Ms. Aron Feingold Head of Corporation Communications & Investor Relations Officer | |
Ms. Heather Erickson Chief of Staff | |
Ms. Whitney Jones Senior Vice President & Chief People Officer | |
Dr. Duncan McKay Senior Vice President & GM of Europe | |
Dr. Nathalie Dubois-Stringfellow Senior Vice President of Product Devel. & Management | |
| Ms. Prathyusha Duraibabu Vice President of Fin. & Principal Accounting Officer |
-
What's the price of Sangamo Therapeutics stock today?
One share of Sangamo Therapeutics stock can currently be purchased for approximately $7.71.
-
When is Sangamo Therapeutics's next earnings date?
Unfortunately, Sangamo Therapeutics's (0R1D.L) next earnings date is currently unknown.
-
Does Sangamo Therapeutics pay dividends?
No, Sangamo Therapeutics does not pay dividends.
-
How much money does Sangamo Therapeutics make?
Sangamo Therapeutics has a market capitalization of 522.66M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 58.34% to 176.23M US dollars.
-
What is Sangamo Therapeutics's stock symbol?
Sangamo Therapeutics, Inc. is traded on the LSE under the ticker symbol "0R1D.L".
-
What is Sangamo Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Sangamo Therapeutics?
Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sangamo Therapeutics's key executives?
Sangamo Therapeutics's management team includes the following people:
- Dr. Alexander D. Macrae Chief Executive Officer, Pres & Director(age: 62, pay: $1,140,000)
- Dr. R. Andrew Ramelmeier Ph.D. Executive Vice President of Technical Operations(age: 63, pay: $542,210)
- Mr. Gary H. Loeb Executive Vice President, Gen. Counsel, Chief Compliance Office & Sec.(age: 55, pay: $487,880)
- Mr. Sung H. Lee Executive Vice President & Chief Financial Officer(age: 54, pay: $320,190)
- Ms. Aron Feingold Head of Corporation Communications & Investor Relations Officer
- Ms. Heather Erickson Chief of Staff
- Ms. Whitney Jones Senior Vice President & Chief People Officer
- Dr. Duncan McKay Senior Vice President & GM of Europe
- Dr. Nathalie Dubois-Stringfellow Senior Vice President of Product Devel. & Management
- Ms. Prathyusha Duraibabu Vice President of Fin. & Principal Accounting Officer
-
How many employees does Sangamo Therapeutics have?
As Jul 2024, Sangamo Therapeutics employs 405 workers.
-
When Sangamo Therapeutics went public?
Sangamo Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 7 Nov 2014.
-
What is Sangamo Therapeutics's official website?
The official website for Sangamo Therapeutics is sangamo.com.
-
Where are Sangamo Therapeutics's headquarters?
Sangamo Therapeutics is headquartered at 501 Canal Blvd, Brisbane California, CALIFORNIA.
-
How can i contact Sangamo Therapeutics?
Sangamo Therapeutics's mailing address is 501 Canal Blvd, Brisbane California, CALIFORNIA and company can be reached via phone at +51 09706000.
Sangamo Therapeutics company profile:
Sangamo Therapeutics, Inc.
sangamo.comLSE
405
Medical - Pharmaceuticals
Healthcare
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Brisbane California, CALIFORNIA 94005
:
ISIN: US8006771062
:
